

Did you know that goat's milk contains prebiotic oligos which are structurally closer to breast milk*

Please contact Pharmabroker 02 8878 9777

* When compared to cow's milk. Source: Urashima and Taufik, 2010.

FIND OUT MORE

Health collaboration

THE University of Sydney, in an attempt to better prepare students for practice in the real world, has created what it calls the "Health Collaboration Challenge."

The Challenge allows participants to learn about teamwork and showcase their creative skills in solving

authentic complex patient

cases, bringing together students from dentistry, nursing, medicine, pharmacy, occupational therapy, speech pathology, physiotherapy, nutrition, diagnostic radiography and exercise physiology.

This year around 1600 students in the health disciplines will compete in teams of six to devise a management plan for a patient with complex health needs and present it back to peers.



IS YOUR BANNER ALIGNED WITH YOUR BUSINESS NEEDS?



Professional Services Leadership

Branding & Marketing Services

Buying & Merchandising Solutions

Contact Lea Bauckham

02 9248 2614

0418 972 402

leanne@instigo.com.au



AFT talks up flying start

LICENSED to sell products in 109 countries around the world, and having raised approximately \$32m at a listing price of \$2.80 at its Initial Public Offering late last year, AFT Pharmaceuticals has recorded an early strong income and cash flow for FY16, according to chairman David Flacks.

Speaking on Fri at the company's inaugural annual general meeting since it was floated on the ASX (PD 11 Dec 2015), Flack said the company recorded total income for FY16 of \$65.8m with operating revenue of \$64m and \$1.8m of licensing income, an operating loss of \$9m and with available cash of more than \$28 million.

Keys to ongoing company growth include completion of development of major innovative products, clinical trials, registration of those products into markets around the world, growth of the existing Australasian business through further product development and licensing of products and expansion of the South East Asian sectors of the business.

As well as planning to broaden

its reach to even more countries, the company is on track to file its Nebuliser nasal device and its first line extension for Maxigesic in the US later this calendar year.

While the vast majority of AFT business is at this stage based in Australasia (97.4%), South-East Asia and the rest of the world have grown by around 300% compared to FY15.

Flacks told shareholders "your company is in good heart and in good hands" having transitioned well from the private to the publicly listed company environment.

New PHARMAC team

NEW Zealand's Pharmaceutical Management Agency (PHARMAC) has appointed three new members to its Consumer Advisory Committee.

They are Te Ropu Poa, Lisa Lawrence and Francesca Holloway, all leaders in their respective advocacy groups across the country.

David Lui of Auckland becomes Committee chair from 01 Aug.

Xiaflex AusPAR

AN AUSTRALIAN Public Assessment Report (AusPAR) has been prepared for Actelion's Xiaflex (collagenase clostridium histolyticum) which is approved for the treatment of adult men with Peyronie's disease with a palpable plaque and penile curvature deformity of at least 30 degrees at the start of therapy.

CLICK HERE for more.

Illegal kratom import

THE US Food and Drug Administration has announced that the U.S. Marshals Service seized more than 100 cases of products labeled as containing kratom.

Mitragyna speciosa, commonly known as kratom, grows naturally in Thailand, Malaysia, Indonesia and Papua New Guinea but the FDA says serious concerns exist about kratom toxicity for multiple organ systems.

The seized products worth around \$150,000 are "unapproved" and "misbranded" drugs under US law.

T2 diabetes mkt boom

NEW therapies coming on line for the treatment of type 2 (T2) diabetes will blow the market out in South-East Asia from \$1.7b to \$2.7b by 2022, a compound annual growth rate (CAGR) of 7.1%, according to business intelligence provider GBI Research.

The region is expected to take up these newer therapies in favour of lower cost generics, the GBI report said.

Six late-stage pipeline products with the potential to "change the treatment paradigm" stand out as offering superior safety, efficacy, and patient compliance.

They are comprised of two offerings each from Novo Nordisk and Merck as well as one each from Eli Lilly and Theracos.

In spite of these trends, generic metformin will remain the mainstay of T2 diabetes therapy both as the initial approach and in combinations, GBI said.

CLICK HERE to access the report.

NICE catchup for AS

ANKYLOSING spondylitis (AS) sufferers in the UK have received new guidance from the National Institute for Health and Care Excellence (NICE) around the use of secukinumab (Cosentyx, Novartis), registered in the UK in May 2016.

The drug has been registered in Australia since Jan last year and funded from Sep last year, Authority Required on the PBS with a cost to taxpayers of \$1,763.70 for two units with five repeats allowed.

CM online registration

NEW guidance for online applications for registered complementary medicines (CMs) has been posted on the TGA's Industry site.

The information applies to new registered complementary medicines (new ARTG entry) and changes to registered complementary medicines (that are already in the ARTG).

Better through experience



1800 810 213

guildinsurance.com.au

Insurance issued by Guild Insurance Limited ABN 55 004 538 863, AFS Licence No. 233791 and subject to terms, conditions and exclusions. For more information call 1800 810 213. GLD3834 Pharmacy Advert 07/2016.



Weekly Comment

Welcome to *PD's* weekly comment feature. This week's contributor is **John Jackson, Director, Project Pharmacist, Monash University.**



Provocative questions about our future

"IF YOU don't know where you are going, any road will get you there"
- Lewis Carroll.

The greater the uncertainty regarding the road ahead, the more important to know where you would like to end up. The profession is facing challenging times. The recent discussion paper on the Review of Remuneration and Regulation has added to the profession's uncertainty. The 140 questions posed in their paper highlight the existential uncertainty we face. They also provide us the opportunity to make a positive statement about our preferred future.

Where would we like to be as a profession? In 2014 the Australian Pharmacy Leaders Forum plus the Pharmacy Board of Australia endorsed "Building upon pharmacists' practice in Australia – A vision for the profession", which identifies functions that pharmacists perform. In summary they are to be accessible; be consumer centred; provide medication management activities; provide primary care; provide preventative & public health services; provide chronic disease management; provide continuity of care activities; promote evidence-guided practice & quality use of medicines; promoting innovation & research; and promote medication safety & quality activities.

This statement articulates our vision for the future. Before you respond to the Remuneration and Regulation Review, perhaps reread it and reflect on our preferred destination. www.psa.org.au

PDC celebration

PHARMACEUTICAL Society of Australia (PSA) national president Joe Demarte has congratulated Perth Diabetes Care (PDC) based at East Victoria Park in Western Australia on the celebration of completing its first year of operation.

"The multidisciplinary clinic for people living with diabetes established by pharmacist and credentialed diabetes educator and former PSA Young Pharmacist of the Year, Teresa Di Franco (pictured),

who is also PSA WA President, and her partner, pharmacist Jeffery Au, is a glimpse into



the future of how 21st Century pharmacies will serve their communities," Demarte said.

"These sorts of innovations are what is required to enable brighter career paths for pharmacists in assisting people in their communities to self-manage their medical condition – in this case diabetes."

Pharmacist in Rio

SYDNEY University Bachelor of Pharmacy graduate Madeline Reimer will represent Australia this week at the Rio Olympics, having been selected for the team earlier this year (*PD* 03 May).

Reimer (pictured) will compete in the women's 3000m steeplechase, more than ten years after winning gold in the same event at the 2004 Commonwealth Youth Games.

She began her pharmacy degree in 2006 and spent eight years out of elite competition to focus on her studies, travel and career in pharmacy, returning in 2013 to train for the Rio Olympics - last year becoming the second fastest female Australian steeplechaser in history.

The 3000m women's steeplechase event kicks off on 13 Aug and combines running and jumping obstacles across 35 barriers, with seven over-water jumps.




Dispensary Corner

A MAKEUP palette designed to look like a chocolate bar on the outside proved a little too appealing for one young girl.

An 18-year-old from California recounted to *The Mirror* her moment of anger then eventual amusement when she found her one-year-old niece had feasted on her expensive Too Faced palette (evidence pictured below).

Her mouth and clothes were covered in smudged shades of brown after she had a good chomp on the makeup kit.

The cautious aunty contacted Too Faced to check her niece didn't need medical help but there were no nasty ingredients to upset her little tummy.



BEWARE the giant dog dropping.

A three metre high inflatable dog dropping has gone missing from the Spanish town of Torrelodones, *BBC News* reports.

Why did the local municipal authorities want it in the first place, you ask?

It was a clever campaign to encourage pet-lovers to pick up after their dogs, but when enthusiastic poop scoopers secreted the super-poop away, they may not have been aware it had cost the local authority €2,400 (more than AU\$3,000) to have it made and installed.

The program was so successful, the council has ordered a replacement inflatable excrement example as well as locating a series of concrete versions around town to make a solid point.

Win with australis

This week *Pharmacy Daily* and Australis are giving away two Oh 2 Glow Foundations each day.

What women want is simple – beautiful, radiant and youthful skin! Australis has the answer with its Oh 2 Glow Foundation that provides a demi-matte, radiant finish.

The fluid formula smooths the skin, evens complexion and disguises imperfections. Available in six shades, Australis Oh 2 Glow Foundation is vegan-friendly and not tested on animals. RRP - \$22.95 Stockists - 1300 650 981

For more information head to our website www.australiscosmetics.com.au.

To win, be the first person from **NSW** or **ACT** to send the correct answer to comp@pharmacydaily.com.au

How many shades in the range?

Check here tomorrow for today's winner.



Pharmacy Daily is Australia's favourite pharmacy industry publication.

Sign up free at www.pharmacydaily.com.au.

Postal address: PO Box 1010, Epping, NSW 1710 Australia

Street address: Suite 1, Level 2, 64 Talavera Rd, Macquarie Park NSW 2113 Australia

P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)

Part of the Business Publishing Group.

Publisher: Bruce Piper info@pharmacydaily.com.au

Reporter: Mal Smith

Contributors: Nathalie Craig, Jasmine O'Donoghue, Bonnie Tai

Advertising and Marketing: Magda Herdzik, Sean Harrigan, Melanie Tchakmadjian

advertising@pharmacydaily.com.au

Business Manager: Jenny Piper accounts@pharmacydaily.com.au

Travel Daily

CRUISE

travelBulletin

business events news

Pharmacy

DAILY

Travel Daily